OBJECTIVE: beta-blockers have provided evidence of improving survival in chronic heart failure patients. Specifically, the Cardiac Insufficiency Bisoprolol Study II has shown a significant reduction in mortality and morbidity among patients with moderate to severe chronic heart failure treated with bisoprolol. Our aim was to investigate the economic consequence of bisoprolol therapy in chronic heart failure patients in Italy. METHODS: Data were derived from the Cardiac Insufficiency Bisoprolol Study II trial. We conducted a cost-effectiveness analysis, comparing standard care with bisoprolol vs. standard care with placebo in the perspective of the Italian National Health Service. We identified and quantified medical costs: drug costs according to the Italian National Therapeutic Formulary; specialist visits for initiation and up-titration of bisoprolol therapy and hospitalizations were quantified based on the Italian National Health Service tariffs (2005). Effects were measured in terms of mortality and morbidity reduction (number of deaths, life years gained and frequency of hospitalizations). We considered an observational period of 1.3 years, i.e. the average follow-up recorded in the trial. Discounting was not performed because of the relatively short follow-up of patients. We conducted one and multi-way sensitivity analyses on unit cost and effectiveness. We also conducted a threshold analysis. RESULTS: The overall cost of care per 1.000 patients treated for 1.3 years was estimated in €2,075,548 in the bisoprolol group and in €2,396,265 in the placebo group, resulting in a net saving of €320,718. The number of additional patients alive with bisoprolol was 55 per 1000 patients; the number of life years gained was 36 at 1.3 year. CONCLUSIONS: Bisoprolol therapy is dominant since it is both less costly and more effective than standard care. Results of sensitivity analysis showed that bisoprolol therapy remains dominant even to changes in unit cost of drug and hospitalizations.
PCV22

CASE-BASED-COSTING VS. MARKOV-MODELLING-A COMPARISON OF COST-EFFECTIVENESS-ANALYSES FOR CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE
Voelkl M, Pirk O, Juenger V Fricke & Pirk GmbH, Nuremberg, Germany OBJECTIVES: To compare two different methods in evaluating cost-effectiveness (CE) of candesartan for patients with chronic heart failure (CHF) in Germany based on the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity)-programme. METHODS: For both analyses, CE was measured by calculating incremental cost-per-avoided-event. Two analytical approaches were chosen examining two treatment groups of the CHARM-programme: "Added" (low left ventricular ejection fraction (LVEF <40%) and "Alternative" (LVEF <40% and intolerant of an ACE inhibitor). The first approach calculated average costs per patient based on all cardiovascular events happened (Hospital admissions due to worsening heart failure, cardiovascular deaths, and cardiovascular procedures). Absolute risk reduction (ARR) to avoid/delay an event also was derived from all events occurring in the clinical trial. The second approach simulated the real life situation of patients with CHF in a Markov-analysis over 12 periods (3 years). Risk tables on mortality and morbidity were derived from Kaplan-Meier-Curves of the CHARM-protocols. ARR was determined through a Monte-Carlo-Simulation for a cohort of 1276 patients. For both approaches, cost calculation was performed from the perspective of the German statutory health insurance (SHI). Base year for costing was 2004. Only direct costs (drug, hospital, general practitioner, specialist, ambulance, rehabilitation) were considered. RESULTS: In the case-basedcosting-approach, the incremental costs to prevent/delay a cardiovascular death or a hospital admission were €516 ("Added") and €1210 ("Alternative"). The Markov-Analysis presented corresponding ratios of €2117 ("Added") and €2814 ("Alternative"). Sensitivity analysis on costs, discounting rates and effects size showed the robustness of both models' results. CONCLU-SIONS: Both analyses showed the cost-effectiveness of candesartan for patients with chronic heart failure. Conducting a simulation that considers real-life-conditions leads to higher ratios, but gives a more precise estimate of the cost-effectiveness of candesartan in a long-term-perspective. To estimate the costs, benefits, and costeffectiveness of valsartan as a treatment of chronic heart failure (CHF) in Hungary. METHODS: A country-specific economic analysis was undertaken by combining within-trial efficacy and resource data from the Valsartan Heart Failure Trial (Val-HeFT) with Hungarian cost estimates. Unit cost estimates were obtained from official data sources of the National Health Found in Hungary and were adjusted to 2004 Hungarian forints. Total within-costs were estimated for hospitalizations, inpatient and outpatient physician services, ambulance transportation, deaths outside the hospital, and outpatient cardiovascular medications. We estimated life expectancy using two different methods, by taking the reciprocal of the mortality rate observed in the trial and based on the percentages of patients who had died during the trial. We compared within-trial inpatient days and number of hospitalizations using a negative binomial model adjusting for follow up. T-tests were used to compare within-trial costs. We also estimated the incremental cost per life year saved. Analyses were conducted for subgroups identified in Val-Heft. RESULTS: The net incremental cost in the valsartan group was 208,766 Ft over 23 months of follow-up. Over the course of the trial, patients treated with valsartan had on average a net incremental cost of 183,619 Ft. Among patients not treated with an ACE inhibitor at baseline, the incremental cost-effectiveness ratio was 402,438 Ft per life-year saved when we estimated life expectancy by taking the reciprocal of the mortality rate observed in the trial. When we estimated life expectancy using the daily hazard rate, the incremental cost-effectiveness ratio was 450,597 Ft per life-year saved. CONCLUSIONS: Valsartan provided clinical benefits at a mean incremental cost of 108,921 Ft per year during the trial. In patients not taking ACE inhibitors, valsartan was economically attractive, increasing survival for a reasonable cost.
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